Table 5.

Summary of adverse events

	Cohort 1			Cohort 2
System organ class	25 M (n = 10)	50 M (n = 10)	P1 (n = 10)	75 M (n = 10)	150 M (n = 10)	P2 (n = 10)
Any adverse event	24 (7)	13 (7)	21 (7)	17 (7)	11 (6)	11 (6)
Blood and lymphatic system disorders	0	1 (1)	1 (1)	0	0	0
Endocrine disorders	0	0	0	1 (1)	0	0
Eye disorders	0	1 (1)	0	0	0	0
Gastrointestinal disorders	1 (1)	0	2 (2)	1 (1)	0	3 (3)
General disorders and administration site conditions	2 (1)	4 (2)	0	9 (6)	4 (3)	0
Infections and infestations	3 (3)	1 (1)	4 (3)	0	1 (1)	1 (1)
Injury, poisoning, and procedural complications	0	0	1 (1)	2 (1)	3 (3)	0
Investigations	2 (2)	1 (1)	1 (1)	0	1 (1)	2 (2)
Metabolism and nutrition disorders	4 (3)	0	3 (3)	0	0	1 (1)
Musculoskeletal and connective tissue disorders	6 (3)	3 (3)	5 (4)	4 (2)	2 (2)	3 (2)
Nervous system disorders	1 (1)	0	1 (1)	0	0	0
Renal and urinary disorders	0	1 (1)	0	0	0	0
Reproductive system and breast disorders	1 (1)	0	0	0	0	0
Respiratory, thoracic, and mediastinal disorders	0	0	0	0	0	1 (1)
Skin and subcutaneous tissue disorders	1 (1)	0	1 (1)	0	0	0
Surgical and medical procedures	2 (1)	0	0	0	0	0
Vascular disorders	1 (1)	1 (1)	2 (1)	0	0	0

Values are shown as number of events (number of patients)

25 M, 50 M, 75 M, 150 M = 25, 50, 75, and 150 million cells, respectively

P1, P2 = placebo 1 and placebo 2, respectively